View Older Stories
-
Horizon Therapeutics (HZNP) Prices 11.8M Share Offering at $71
-
Horizon Therapeutics plc Announces Pricing of Public Offering of Ordinary Shares
-
Horizon Therapeutics (HZNP) Announces Proposed $700M Public Offering of Ordinary Shares
-
Horizon Therapeutics plc Announces Proposed Public Offering of Ordinary Shares
-
Citi Upgrades Horizon Pharma (HZNP) to Buy
-
Horizon Pharma plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Horizon Pharma (HZNP) Prices 12.245M Share Common Offering at $24.50/Sh
-
Horizon Pharma plc Announces Pricing of Public Offering of Ordinary Shares
-
Horizon Pharma (HZNP) to Offer $300M in Common Stock
-
Horizon Pharma plc Announces Proposed Public Offering of Ordinary Shares
-
Horizon Pharma (HZNP) PT Raised to $21 at Citi
-
Citi Downgrades Horizon Pharma (HZNP) to Neutral
-
Horizon Pharma (HZNP) PT Raised to $18 at Citi on 2018 Outlook; 'Remain Constructive... Stability in Primary Care Franchise'
-
Horizon Pharma (HZNP) PT Lowered to $13 at Citi; Remains Positive on Orphan Drug Valuation and Primary Care Earnings
-
Citi Upgrades Horizon Pharma (HZNP) to Buy
-
Complete Donald Trump Stock Impact Guide
-
Notable Mergers and Acquisitions 9/12: (AGU)/(POT) (HPQ) (HZNP)/(RPTP) (OTEX)
-
Horizon Pharma plc (HZNP) to Acquire Raptor Pharmaceutical (RPTP) for $800M
-
Horizon Pharma plc to Acquire Raptor Pharmaceutical Corp. as Further Step in Building Leading Rare Disease Business
-
Pre-Open Stock Movers 04/12: (FOLD) (ARNA) (HLX) Higher; (HZNP) (OZM) (JNPR) Lower (more...)
-
Horizon Pharma (HZNP) 'Disappointed' in Depomed's (DEPO) Poison Pill Provision
-
Horizon Pharma plc Responds to Depomed's Adoption of a Poison Pill
-
Horizon Pharma (HZNP) Proposes to Acquire Depomed (DEPO) for $29.25/Share
-
Horizon Pharma plc Proposes to Acquire Depomed, Inc. for $29.25 per Share in an All-Stock Transaction, Representing a 42 Percent Premium to Depomed's Shareholders
-
Horizon Pharma plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Pre-Open Stock Movers 04/16: (MNOV) (TZOO) (NFLX) (PNRA) Higher; (PTX) (SNDK) (FNRG) Lower (more...)
-
Horizon Pharma (HZNP) Prices Larger 15.35M Common Offering at $28.25/Share
-
Horizon Pharma plc Announces Pricing of Public Offering of Ordinary Shares
-
Horizon Pharma (HZNP) to Offer 12M Common Shares
-
Horizon Pharma plc Announces Proposed Public Offering of Ordinary Shares
-
Pre-Open Stock Movers 04/10: (GE) (HZNP) (NFLX) Higher; (EXTR) (MDCO) (CTXS) Lower (more...)
-
Notable Mergers and Acquisitions 3/30: (CTRX)/(UNH) (TEVA)/(ASPX) (HZNP)/(HPTX) (ICEL)
-
Horizon Pharma (HZNP) to Acquire Hyperion Therapeutics (HPTX) in $1.1B Deal
-
Horizon Pharma plc to Acquire Hyperion Therapeutics, Inc. for $46.00 per Share or $1.1 Billion in Cash
-
Citi Starts Horizon Pharma (HZNP) at Buy
-
Horizon Pharma (HZNP) Prices 11.66M Common Secondary at $12.05/Share
-
Horizon Pharma (HZNP) Reports 11.66M Share Secondary Offering
-
UPDATE: Notable Mergers and Acquisitions of the Day 03/19: (JPM) (HZNP) (SAL) (DHX)
-
Pre-Open Stock Movers 3/19: (HZNP) (PRTA) (KBH) Higher; (RENN) (RBCN) (KNDI) (ORCL) Lower (more...)
-
Horizon Pharma (HZNP) to Acquire Vidara Therapeutics in $660M Deal

